NCT04419623View on ClinicalTrials.gov

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

July 9, 2020

Primary Completion Date

September 22, 2020

Study Completion Date

December 15, 2020

Conditions
COVID-19Sars-CoV2CancerSolid TumorCarcinomaBlood Cancer
Interventions
DRUG

TL-895

TL-895, administered by mouth

Trial Locations (2)

30912

Georgia Cancer Center, Augusta

43210

The Ohio State Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY

NCT04419623 - A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer | Biotech Hunter | Biotech Hunter